Filters
Purpose limitation and data minimisation: key considerations for AI training in the life sciences sector
The use of real-world evidence data to train AI models is becoming a critical component in advancing research and drug development. We explore how two of the GDPR's guiding principles are more than just regulatory requirements.
3 of 10 Insights
Selecting your AIA notified body
Manufacturers/providers of medical devices that, according to the EU AI Act, include a high-risk AI system (HRAIS) require a notified body assessment of their technical documentation and/or quality management system should urgently consider which notified body to appoint.
6 of 10 Insights
Data privacy in AI due diligence
AI has become an integral part of business operations across various industries. Its deployment demands careful legal and strategic considerations. Before integrating AI systems in a company’s workflows, thorough diligence should be conducted.
7 of 10 Insights
The regulation of clinical trials in which AI is deployed
While the AI Act is not applicable to certain research uses of AI, these exemptions do not apply to the use of AI in clinical trials, where a myriad of regulation and guidance has potential application.
2 of 10 Insights
Damages for Incorrect SCHUFA Report: Analysis of the BGH Ruling of 28 January 2025 (VI ZR 183/22)
Advising Lessmore on its sale to Miniclip
Taylor Wessing advises insolvency administrator on the sale of Swedish Green Wood Sverige AB to Profura
Taylor Wessing advises insolvency administrator on the sale of the Romanian sawmill ZG Timber Sebes to Kronospan
ECJ on scoring: Comprehensive GDPR triggered information obligations
